ARTICLE | Strategy

IMNR can't agree with partner

February 22, 1994 8:00 AM UTC

The Immune Response Corp. and Rhone-Poulenc Rorer are putting the future management of clinical trials of their AIDS vaccine into the hands of arbitrators. IMNR and Rhone-Poulenc filed separate arbitration motions before the American Arbitration Association in St. Louis to decide their differences with respect to the management of additional clinical trials and the regulatory process.

The companies formed their 50-50 Immunization Products Ltd. joint venture in 1988 to develop the AIDS therapeutic. IMNR and Rhone-Poulenc each contributed about $25 million to the joint venture through last December...